Coloplast A/S - Full-Year Financial Results 2023/24 [Yahoo! Finance]
COLOPLAST AS SP/ADR (CLPBY)
NASDAQ:AMEX Investor Relations:
coloplast.com/investor-relations
Company Research
Source: Yahoo! Finance
Coloplast delivered Q4 organic growth of 8% and an EBIT margin of 26%, which was negatively impacted by extraordinary costs and currencies. Reported revenue in DKK grew 12% with 3%-pts contribution from the Kerecis acquisition (two months). Organic growth rates by business area: Ostomy Care 6%, Continence Care 10%, Voice and Respiratory Care 12%, Advanced Wound Care 10% (Advanced Wound Dressings 4%) and Interventional Urology 7%. Growth in Chronic Care was broad-based and includes improvement in growth in the US which benefited from the resolution of the supply disruptions. Ostomy Care growth was held back by Emerging markets, reflecting a higher baseline in Q4 last year. Continence Care growth was broad-based across segments and includes significant contribution from Luja™*. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Care reflects one-month organic contribution from Kerecis and doubl
Show less
Read more
Impact Snapshot
Event Time:
CLPBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLPBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLPBY alerts
High impacting COLOPLAST AS SP/ADR news events
Weekly update
A roundup of the hottest topics
CLPBY
News
- Coloplast A/S (OTCMKTS: CLPBY) was upgraded by analysts at UBS Group AG from a "strong sell" rating to a "hold" rating.MarketBeat
- Biolevate's raises €6M to helps medical writers keep up with the pace of new drugs [Yahoo! Finance]Yahoo! Finance
- Biolevate's raises €6M to helps medical writers keep up with the pace of new drugs [TechCrunch]TechCrunch
- Coloplast A/S (OTCMKTS: CLPBY) was upgraded by analysts at Hsbc Global Res from a "moderate sell" rating to a "hold" rating.MarketBeat
- North America Ostomy Drainage Bags (Colostomy, Ileostomy, and Urostomy) Market Outlook 2023-2024 & 2028 with Competitive Analysis of Coloplast, ConvaTec, B. Braun, Hollister, and Salts Healthcare [Yahoo! Finance]Yahoo! Finance